New Two-Step attack on aggressive blood cancer enters testing
NCT ID NCT07257055
Summary
This study is testing a two-step treatment for people newly diagnosed with a high-risk form of mantle cell lymphoma (MCL), a type of blood cancer. First, participants receive a combination of two drugs (BTKi and rituximab). Then, they receive a third drug (glofitamab) to try to better control the cancer. The main goals are to see if this approach is safe and effective for these patients.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MCL are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
MD Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.